The Latin America, Middle East and Africa Antibody Therapeutics Market would witness market growth of 17.0 % CAGR during the forecast period (2023-2030).
Antibody-drug conjugates (ADCs) represent a burgeoning trend in targeted cancer therapy. ADCs combine the specificity of monoclonal antibodies with potent cytotoxic agents, allowing for precise delivery of chemotherapy to cancer cells while minimizing damage to healthy tissues. Developing novel ADCs with improved payload delivery and reduced toxicity is a focus of ongoing research. The trend towards personalized medicine is influencing antibody therapeutics development. Biomarker identification and patient stratification strategies are becoming integral in clinical trial design. Tailoring antibody therapies to specific patient subgroups based on biomarker profiles enhances treatment outcomes and minimizes unnecessary exposure to treatments with limited efficacy.
Integrating AI and machine learning in antibody discovery and development accelerates drug development. These methods enable quick analysis of massive datasets, prediction of antibody-antigen interactions, and lead candidate optimization. AI-driven approaches enhance the efficiency of antibody engineering, reducing development timelines and costs. Combinatorial approaches involving multiple antibodies or combining antibodies with other treatment modalities are gaining traction. Synergistic effects can be achieved by targeting different aspects of disease pathways. Combination therapies, such as combining checkpoint inhibitors with other immune modulators, are explored to enhance therapeutic responses. Exploring novel antibody formats beyond traditional monoclonal antibodies is a growing trend. Single-domain antibodies (nanobodies), antibody fragments, and multispecific antibodies are gaining attention for their unique properties, such as improved tissue penetration and rapid clearance. These formats open new possibilities for therapeutic innovation and more convenient administration routes.
The UAE's strategic focus on becoming a biotechnology hub has catalyzed the growth of the antibody therapeutics. It plays a crucial role in oncology, and expanding these treatments in the UAE contributes to advancements in cancer care. The UAE's biopharmaceutical industry is involved in the development of biosimilar antibodies. Expanding antibody therapeutics ensures that patients in the UAE have access to advanced and targeted therapies. The UAE's investment in biomanufacturing capabilities supports the local production of antibody therapeutics. Due to these aspects, the market will expand across the LAMEA region in upcoming years.
The Brazil market dominated the LAMEA Antibody Therapeutics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $12,158.1 million by 2030. The Argentina market is exhibiting a CAGR of 17.7% during (2023 - 2030). Additionally, The UAE market would experience a CAGR of 16.7% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Others. Based on Format, the market is segmented into, Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody, Antibody fragment & Others. Based on Source, the market is segmented into Human, Humanized, and Chimeric. Based on End User, the market is segmented into Hospitals, Long-term care facilities, and Others. Based on Disease Areas, the market is segmented into Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology, Oncology, Infectious Diseases, Immunology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.
Antibody-drug conjugates (ADCs) represent a burgeoning trend in targeted cancer therapy. ADCs combine the specificity of monoclonal antibodies with potent cytotoxic agents, allowing for precise delivery of chemotherapy to cancer cells while minimizing damage to healthy tissues. Developing novel ADCs with improved payload delivery and reduced toxicity is a focus of ongoing research. The trend towards personalized medicine is influencing antibody therapeutics development. Biomarker identification and patient stratification strategies are becoming integral in clinical trial design. Tailoring antibody therapies to specific patient subgroups based on biomarker profiles enhances treatment outcomes and minimizes unnecessary exposure to treatments with limited efficacy.
Integrating AI and machine learning in antibody discovery and development accelerates drug development. These methods enable quick analysis of massive datasets, prediction of antibody-antigen interactions, and lead candidate optimization. AI-driven approaches enhance the efficiency of antibody engineering, reducing development timelines and costs. Combinatorial approaches involving multiple antibodies or combining antibodies with other treatment modalities are gaining traction. Synergistic effects can be achieved by targeting different aspects of disease pathways. Combination therapies, such as combining checkpoint inhibitors with other immune modulators, are explored to enhance therapeutic responses. Exploring novel antibody formats beyond traditional monoclonal antibodies is a growing trend. Single-domain antibodies (nanobodies), antibody fragments, and multispecific antibodies are gaining attention for their unique properties, such as improved tissue penetration and rapid clearance. These formats open new possibilities for therapeutic innovation and more convenient administration routes.
The UAE's strategic focus on becoming a biotechnology hub has catalyzed the growth of the antibody therapeutics. It plays a crucial role in oncology, and expanding these treatments in the UAE contributes to advancements in cancer care. The UAE's biopharmaceutical industry is involved in the development of biosimilar antibodies. Expanding antibody therapeutics ensures that patients in the UAE have access to advanced and targeted therapies. The UAE's investment in biomanufacturing capabilities supports the local production of antibody therapeutics. Due to these aspects, the market will expand across the LAMEA region in upcoming years.
The Brazil market dominated the LAMEA Antibody Therapeutics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $12,158.1 million by 2030. The Argentina market is exhibiting a CAGR of 17.7% during (2023 - 2030). Additionally, The UAE market would experience a CAGR of 16.7% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Others. Based on Format, the market is segmented into, Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody, Antibody fragment & Others. Based on Source, the market is segmented into Human, Humanized, and Chimeric. Based on End User, the market is segmented into Hospitals, Long-term care facilities, and Others. Based on Disease Areas, the market is segmented into Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology, Oncology, Infectious Diseases, Immunology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration- Intravenous
- Subcutaneous
- Others
- Monoclonal Antibody
- Polyclonal Antibody Therapy
- Bispecific Antibody
- Antibody fragment & Others
- Human
- Humanized
- Chimeric
- Hospitals
- Long-term care facilities
- Other
- Autoimmune & Inflammatory Diseases
- Neurology
- Osteology
- Hematology
- Oncology
- Infectious Diseases
- Immunology
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- F.Hoffmann-La Roche Ltd
- AbbVie, Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Merck KGaA
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Sanofi S.A.
- Novartis AG
- Biogen, Inc.
- Amgen, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. LAMEA Antibody Therapeutics Market by Route of Administration
Chapter 6. LAMEA Antibody Therapeutics Market by Format
Chapter 7. LAMEA Antibody Therapeutics Market by Source
Chapter 8. LAMEA Antibody Therapeutics Market by End User
Chapter 9. LAMEA Antibody Therapeutics Market by Disease Areas
Chapter 10. LAMEA Antibody Therapeutics Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- AbbVie, Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Merck KGaA
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Sanofi S.A.
- Novartis AG
- Biogen, Inc.
- Amgen, Inc.
Methodology
LOADING...
